NYKD — Nykode Therapeutics ASA Share News
0.000.00%
- NOK870.25m
- NOK450.97m
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026
Brief: Nykode Therapeutics Q1 Operating Loss USD 6.5 Million
Brief: Nykode Presents Additional Immunogenicity Data From VB-C-03 Trial
Brief: Nykode Therapeutics Q4 Operating Loss At $8.1 Million
Brief: Nykode Therapeutics Announces New Interim Data From Vb-C-03 Trial
Brief: Nykode Therapeutics Elects New Chair Of Board
Brief: Nomination Committee Of Nykode Recommends Barbara Krebs-Pohl As New Chair Of Board
Brief: Nykode Therapeutics Q3 Total Revenue And Other Income Down At USD 0.1 Mln
Brief: Nykode Receives U.S. Patent For Neoantigen Selection Method
Brief: Nykode Therapeutics Q2 Net Profit $0.9 Mln
Brief: Nykode Therapeutics Q1 Total Revenue And Other Income $0.1 Mln
Brief: Nykode Therapeutics Proposes Dividend Of NOK 1.00 Per Share
Brief: Nykode CEO, CSO, CFO Withdraw Resignations
Brief: Norda Acquires 3 Mln Shares In Nykode Therapeutics
Brief: Nykode Therapeutics Top Managers Resign
Brief: Nykode Therapeutics Q4 Total Revenue And Other Income At USD 6.9 Million